Qube Research & Technologies (QRT)
AVIR icon

Qube Research & Technologies (QRT)’s Atea Pharmaceuticals AVIR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,235
Closed -$27.3K – 3304
2024
Q2 		$27.3K Sell
8,235
-18,154
-69% -$67.7K ﹤0.01% 2843
2024
Q1 		$107K Sell
26,389
-26,649
-50% -$104K ﹤0.01% 3277
2023
Q4 		$162K Buy
53,038
+13,422
+34% +$40.6K ﹤0.01% 2905
2023
Q3 		$119K Buy
39,616
+6,829
+21% +$23.2K ﹤0.01% 2606
2023
Q2 		$123K Buy
+32,787
New +$123K ﹤0.01% 1912
2022
Q3 		– Sell
-60,067
Closed -$426K – 2498
2022
Q2 		$426K Buy
60,067
+20,892
+53% +$143K ﹤0.01% 1474
2022
Q1 		$283K Buy
+39,175
New +$266K ﹤0.01% 1815

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AVIR Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Atea Pharmaceuticals (AVIR) in Q3 2024, closing a stake of 8,235 shares — an estimated $27.3K sold.

Qube Research & Technologies (QRT) first reported a position in AVIR in Q1 2022 and held it in 7 quarters. The position peaked at $426K in Q2 2022. 108 funds tracked by Wall St. Rank hold AVIR as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Atea Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 8,235 Atea Pharmaceuticals shares in Q3 2024, an estimated $27.3K.
  • Qube Research & Technologies (QRT) first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Qube Research & Technologies (QRT)'s Atea Pharmaceuticals position peaked at $426K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.